{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:07:13Z","timestamp":1794604033903,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.semarthrit.2021.11.001","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T15:31:39Z","timestamp":1636212699000},"page":"1370-1377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains"],"prefix":"10.1016","volume":"51","author":[{"given":"George A","family":"Wells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tugwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Tomasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Guillemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara J","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverley J","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Grosskleg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Merkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"March","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorcas E","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2021.11.001_bib0001","series-title":"Guidance for industry, draft guidance","year":"2017"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0002","unstructured":"Guideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis. European medicines agency, CPMP\/EWP\/556\/95 Rev. 2, committee for medicinal products for human use, December 2017."},{"issue":"Suppl. 39","key":"10.1016\/j.semarthrit.2021.11.001_bib0003","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.11.001_bib0004","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/ijr.13.24","article-title":"Clinical disease activity assessments in rheumatoid arthritis","volume":"8","author":"Salaffi","year":"2013","journal-title":"Int J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0005","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13063-016-1402-5","article-title":"A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes","volume":"17","author":"Ibrahim","year":"2016","journal-title":"Trials"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.11.001_bib0006","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/art.39098","article-title":"Disease activity in rheumatoid arthritis and the risk of cardiovascular events","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001595","article-title":"Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure","volume":"7","author":"Burmester","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0008","doi-asserted-by":"crossref","DOI":"10.2147\/DHPS.S4334","article-title":"Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors","author":"Rostom","year":"2009","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0009","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3899\/jrheum.090168","article-title":"A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract","volume":"37","author":"Chan","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0010","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jclinepi.2004.11.028","article-title":"Powering our way to the elusive side effect: a composite outcome \u2018basket\u2019 of predefined designated endpoints in each organ system should be included in all controlled trials","volume":"58","author":"Tugwell","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0011","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0012","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0013","first-page":"216","article-title":"Adverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world study","volume":"33","author":"Lampropoulos","year":"2015","journal-title":"Clin. Exp. Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0014","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American college of rheumatology\/European league against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0015","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jclinepi.2006.10.020","article-title":"Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns","volume":"60","author":"Ferreira-Gonz\u00e1lez","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0016","doi-asserted-by":"crossref","first-page":"c3920","DOI":"10.1136\/bmj.c3920","article-title":"Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review","volume":"341","author":"Cordoba","year":"2010","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0017","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jclinepi.2006.10.024","article-title":"Weighing the pros and cons for composite outcomes in clinical trials","volume":"60","author":"Freemantle","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0018","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1002\/sim.1300","article-title":"Combined endpoints: can we use them?","volume":"21","author":"Lubsen","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0019","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1472-8206.2005.00370.x","article-title":"Some issues with composite endpoints in clinical trials","volume":"19","author":"Chi","year":"2005","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.athoracsur.2012.05.027","article-title":"Weighting composite endpoints in clinical trials: essential evidence for the heart team","volume":"94","author":"Tong","year":"2012","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0021","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ahj.2010.12.026","article-title":"Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial","volume":"161","author":"Armstrong","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0022","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/STROKEAHA.110.600106","article-title":"Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years","volume":"42","author":"Hong","year":"2011","journal-title":"Stroke"},{"issue":"Suppl. 85","key":"10.1016\/j.semarthrit.2021.11.001_bib0023","first-page":"S65","article-title":"The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28)","volume":"32","author":"van Riel","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0024","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/01.CIR.0000023219.51483.66","article-title":"Lessons learned from recent cardiovascular clinical trials: part I","volume":"106","author":"DeMets","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0025","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0197-2456(92)90020-Z","article-title":"A method of assigning scores to the components of a composite outcome: an example from the MITI trial","volume":"13","author":"Hallstrom","year":"1992","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0026","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.cardfail.2005.08.350","article-title":"Key issues in endpoint selection for heart failure trials: composite end points","volume":"11","author":"Neaton","year":"2005","journal-title":"J Card Fail"},{"issue":"7491","key":"10.1016\/j.semarthrit.2021.11.001_bib0027","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/bmj.330.7491.594","article-title":"Validity of composite endpoints in clinical trials","volume":"330","author":"Montori","year":"2005","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.11.001_bib0028","doi-asserted-by":"crossref","DOI":"10.5811\/westjem.2018.4.38383","article-title":"Understanding the use of composite endpoints in clinical trials","volume":"19","author":"McCoy","year":"2018","journal-title":"Western J Emerg Med"},{"key":"10.1016\/j.semarthrit.2021.11.001_bib0029","series-title":"Users\u2019 guides to the medical literature: a manual for evidence-based clinical practice","article-title":"Composite End Points (Chapter 12.4)","author":"Ferreira-Gonzales","year":"2015"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.11.001_bib0030","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1080\/13696998.2020.1797755","article-title":"Composite outcome measurement in clinical research: the triumph of illusion over reality?","volume":"23","author":"McKenna","year":"2020","journal-title":"J Med Econ"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T04:39:09Z","timestamp":1672720749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221001967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0049017221001967"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}